Stefania Mosconi

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Stefano Cascinu · 5 shared papers, 2014–2025 · strength 0.42
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancr… DOI 10.1016/j.ejca.2021.02.023↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
2. Alessandro Bittoni · 4 shared papers, 2015–2025 · strength 0.39
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancr… DOI 10.1016/j.ejca.2021.02.023↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
3. Andrea Spallanzani · 3 shared papers, 2021–2025 · strength 0.35
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancr… DOI 10.1016/j.ejca.2021.02.023↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
4. Michele Reni · 3 shared papers, 2018–2025 · strength 0.32
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
   • Paper Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a… DOI 10.1016/s2468-1253(18)30081-5↗
5. Mario Scartozzi · 3 shared papers, 2015–2025 · strength 0.29
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
   • Paper The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer pa… DOI 10.18632/oncotarget.5197↗
6. Marina Macchini · 2 shared papers, 2021–2025 · strength 0.25
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
7. Elisa Giommoni · 2 shared papers, 2021–2025 · strength 0.25
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
8. Maria Grazia Rodriquenz · 2 shared papers, 2021–2025 · strength 0.25
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
9. Mariacristina Di Marco · 2 shared papers, 2021–2025 · strength 0.25
   • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
10. Silvia Bozzarelli · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
11. Giulia Orsi · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
12. Ingrid Garajová · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
13. Guido Giordano · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
14. Ilario Giovanni Rapposelli · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
15. Monica Niger · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
16. Giampaolo Tortora · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
17. Michèle Milella · 2 shared papers, 2021–2025 · strength 0.25
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
18. Marta Chiaravalli · 2 shared papers, 2018–2025 · strength 0.23
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
    • Paper Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a… DOI 10.1016/s2468-1253(18)30081-5↗
19. Roberto Labianca · 4 shared papers, 2012–2021 · strength 0.22
    • Paper Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancr… DOI 10.1016/j.ejca.2021.02.023↗
    • Paper Treatment of advanced pancreatic cancer. DOI 10.1093/annonc/mds355↗
    • Paper The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer pa… DOI 10.18632/oncotarget.5197↗
20. Rossana Berardi · 3 shared papers, 2014–2021 · strength 0.17
    • Paper Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancr… DOI 10.1016/j.ejca.2021.02.023↗
    • Paper The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer pa… DOI 10.18632/oncotarget.5197↗
    • Paper Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. DOI 10.1016/j.dld.2013.09.020↗
21. Letizia Procaccio · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
22. Sara Lonardi · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
23. Francesca Bergamo · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
24. Lisa Salvatore · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
25. Enrico Vasile · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.